Targeting residual cardiovascular risk in the statin era: cholesterol or inflammation?
Open Access
- 4 May 2023
- journal article
- editorial
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 44 (22) , 1973-1975
Abstract
Comment on ‘Inflammation and cholesterol as predictors of cardiovascular events among patients receiving statin therapy: a collaborative analysis of three randomised trials’, which was published in The Lancet, https://doi.org/10.1016/S0140-6736(23)00215-5.Keywords
This publication has 12 references indexed in Scilit:
- Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trialsEuropean Heart Journal, 2021
- Colchicine in Patients with Chronic Coronary DiseaseNew England Journal of Medicine, 2020
- Low-dose colchicine: a new tool in the treatment of chronic coronary disease? Comment on the low-dose colchicine (LoDoCo)2 trialEuropean Heart Journal, 2020
- Targeting cardiovascular inflammation: next steps in clinical translationEuropean Heart Journal, 2020
- Efficacy and Safety of Low-Dose Colchicine after Myocardial InfarctionNew England Journal of Medicine, 2019
- Promises and challenges of targeting inflammation to treat cardiovascular disease: the post-CANTOS eraEuropean Heart Journal, 2019
- Alirocumab and Cardiovascular Outcomes after Acute Coronary SyndromeNew England Journal of Medicine, 2018
- Antiinflammatory Therapy with Canakinumab for Atherosclerotic DiseaseNew England Journal of Medicine, 2017
- Evolocumab and Clinical Outcomes in Patients with Cardiovascular DiseaseNew England Journal of Medicine, 2017
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005